AztraZeneca: What Science Can Do
Please join us Wednesday, March 15 for dinner and a presentation by Mitchell Chan of AstraZeneca, North America.
Dinner: Choice of four made to order entrees including filet mignon and fish
Registration also includes one free drink
Free to Members! Only $10 for Non-Members and Registered CFA Program Candidates if pre-paid via PayPal!
Event Eligible for one hour CFA Institute CE Credit.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least 6 new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms -- immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates -- and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
Director of Investor Relations, AstraZeneca, North America
Mitchell Chan is responsible for managing AstraZeneca’s Investor Relations in North America. In this capacity he is responsible for Oncology and North American operations. Before AstraZeneca, Mitchell worked at Genentech/Roche, where he held roles in Mergers & Acquisitions, Commercial Finance, and Global Product Development Finance. He graduated with a BSc in Biochemistry, an MSc in Molecular Biophysics, and an MBA from the University of Toronto.